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Abstract Background Generic uptake will increasingly
be promoted by governments in the face of increasing
healthcare costs and global economic uncertainties. Ob-
jective The purpose of this study was to investigate atti-
tudes towards generic substitution among community
pharmacists, with a focus on the perception of the efficacy,
knowledge of the generics characteristics, as well as the
willingness to recommend generic substitution. Setting
Community pharmacies in Poland. Method The survey was
conducted in 2013 by telephone interviews with 802
holders of an MSc degree in pharmacy working as com-
munity pharmacists. Stratified sampling was implemented
to make the study representative in geographic terms. Main
outcome measure Pharmacists’ attitudes towards generics
drugs. Results The study showed that only 40 % of phar-
macists always inform patients about their right to choose a
generic substitute. It was also shown that the less time a
pharmacist has been practising, the less likely they are to
invite consumers to choose between generic and innovator
products. The likelihood of informing was not affected by
pharmacist’s sex or age, or by pharmacy location or status
(chain vs. independent pharmacy) (p[ 0.05). Pharmacists
varied in their approach to their statutory obligation to
inform about a generic; a more or less equal share of
respondents were either in favour or against it. Approxi-
mately 60 % pharmacists were shown to be familiar with
the definition of a generic medicine. Pharmacists with
shorter time of practice proved to know more about
generics. However, more than 30 % respondents failed to
choose the correct statement on generic versus reference
medicine dosage. The majority of respondents (67 %)
believed there are no differences in efficacy between
generics and innovator drugs, whereas 31 % claimed that
original brands could be more effective. A significant
correlation was demonstrated between the views of phar-
macists on the therapeutic efficacy and their willingness to
substitute for generics whenever permitted by a physician.
Conclusion It is important to address all concerns phar-
macists may have over generics, for example by imple-
menting comprehensive awareness-raising campaigns.
Also, pharmacotherapy monitoring systems (i.e. provided
in a framework of pharmaceutical care) could be consid-
ered to identify any safety or quality concerns that may
arise.
Keywords Educational campaigns  Generic
substitution  Pharmacists’ knowledge  Pharmacists’
opinions  Poland  Quality  Safety  Therapeutic efficacy
Impacts on practice
• Pharmacists who are against the legal obligation to
inform consumers about optional substitution also have
a more skeptical opinion on the therapeutic efficacy of
generics.
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• An education campaign for pharmacists should be
planned to refresh the knowledge on generic medicines
of especially the older pharmacists.
Introduction
During the 1980s and 1990s, most new legal regulations
were intended to curtail the increasing costs of general
medical care, with medicine being the major cost in
healthcare globally [1]. Generally speaking, increasing
drug expenditure over the past 10 years can be attributed to
supply (the introduction of new expensive technologies)
and demand (an ageing society and an increased prevalence
of some health conditions). Due to the underlying
assumption that market competition would not guarantee
affordable prices alone, a wide range of regulatory inter-
ventions were implemented [2].
Generic drugs represent a major share in the drug market
in Poland [1]. Drug expenditure in Poland is one of the
lowest in Europe—$306 per capita in 2011 [3]. However,
patient co-payment for drugs in Poland is the highest
among all of the OECD countries, 60.8 % in 2009 with an
increase of 3.4 % between 2000 and 2009 [4] (approxi-
mately 35 % of Poles reported that they could not afford to
buy prescribed drugs and almost 8 % admitted to having
resigned from or discontinued treatment for financial rea-
sons [5]). According to the Polish Drug Reimbursement
Act of May 2011, public spending on drug reimbursement
cannot exceed 17 % of overall public spending on health-
care services guaranteed under the financial plan of the
National Health Fund (NFZ).
Since EU accession, Polish legislative and regulatory
framework has been harmonized with EU directives gov-
erning production, market placement, advertising and the
marketing of medicinal products, in addition to relevant
supervision and quality control regulations [1]. In Poland,
GMP requirements for the pharmaceutical industry are
governed by the Regulation of the Minister of Health of 1
October 2008 concerning Good Manufacturing Practice
requirements (Journal of Laws Dz.U. 2008.184.1143).
The introduction of generic medicines to the market has
a positive and statistically significant effect on reducing the
prices of innovator drugs [7]. Furthermore, generics are
believed to be a key factor in fuelling competition in the
pharmaceutical market [8]. The price of medicines is not
always determined by the balance between supply and
demand. Currently, the pharmaceutical sector is heavily
influenced by laws and regulations introduced by the
government, such as official lists of reimbursed drugs, or
detailed marketing authorization procedures. Pharmacies
are obliged to inform customers that they can opt for a
generic drug instead of the innovator medicine they have
been prescribed; this should be indicated in written form in
a visible and accessible location in the premises. Since the
Drug Reimbursement Act of 1st January 2012, the duty to
inform patients of generic substitution has been limited to
reimbursement drugs only [9]. Polish drug pricing policy
aims to add generics to the list of drugs eligible for reim-
bursement. Prescribing doctors still have the right to
specify whether generic drug substitution is allowed and
there is no obligation to include the international non-
proprietary name (INN) in drug prescriptions [10].
The current definition of ‘generic medicinal products’ is
found in Directive 2001/83/EC, Article 10(2)(b), which
states that a generic medicinal product is a product which
has the same qualitative and quantitative composition of
active substances and the same pharmaceutical form as the
reference medicinal product, and whose bioequivalence
with the reference medicinal product has been demon-
strated by appropriate bioavailability studies [6]. Tests are
carried out according to the European guidelines and rec-
ommendations for bioavailability and bioequivalence
studies (CPMP/EWP/QWP 1401/98), under which 90 % of
confidence limits for Cmax and AUC should be between 80
and 125 %. In certain defined circumstances the 80–125 %
range can be adjusted, for example, to address the concerns
derived from literature reports describing the intensifica-
tion of disease symptoms after switching NTI drug for a
generic [11], the EMA introduced a tighter acceptance
range for NTI drugs. EU guidelines define a
90.00–111.11 % acceptance range for the AUC of all NTI
drugs. The Committee for Human Medicinal Products
(CHMP) decides whether a particular drug meets the NTI
drug criteria. For special efficacy and safety reasons, the
CHMP can decide to reduce the Cmax acceptance range to
90–111.11 %.
The main goal in bioequivalence testing is to detect
variations in absorption and not test how the drugs work as
they both contain the same active substance. Variations in
absorption can be observed with each subsequent dose due
to intra-subject variability. By definition, generic and
branded drugs both contain exactly the same active sub-
stance at precisely the same dose. Thus, generic versus
brand drug absorption would have to be tested for: possible
absorption variations attributed to the presence of qualita-
tively and quantitatively different excipients or variations
in technological procedures used in drug production and
taking into account intra-subject variability.
Doing this can be challenging, as intra-subject vari-
ability can mask possible absorption variations of identical
active molecules from two different tablets (generic vs.
brand-name drugs). The testing method must be highly
sensitive to detect variations (instead of conformities) in
the absorption of the active substance from the intestines
into the bloodstream; it must answer the question of
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whether absorption is unaffected by excipients. It is
therefore essential that all mechanisms which transport the
active substance through the intestinal wall are present in
the test, including epithelial cell enzymes, transport pro-
teins responsible for active substance delivery from the
blood into the intestinal lumen and vice versa, as well as
enzyme and transporter inhibitors in cells. This is why
healthy, young individuals with normal intestinal wall
functions are chosen to test bioequivalence [12].
Pharmacists play a key role in managing drug expen-
diture without losing therapeutic efficacy [13]. However,
the role of a community pharmacist in selecting generics is
complex [14–17]. Not only do they select a bioequivalent
medicine, but they also educate consumers on issues
around generic substitution, such as patient compliance.
They also help to avoid patient confusion due to changes in
brand medication and provide information on the quality
and safety of generics to healthcare providers [14–17]. The
attitude of consumers and pharmacists may be one barrier
regarding the uptake of generics. Generics are perceived as
less effective and less safe than innovator drugs. Therefore
they are insufficiently used, which is the main reason why
health care systems worldwide are ineffective, according to
the World Health Organization [18].
Aim of the study
This study aims to deliver baseline data to support the
implementation of a generic substitution policy based on
the perceptions and behaviour of pharmacists, and to
evaluate views on generic medicines among community
pharmacists in Poland. In order to do this, 802 pharmacists
were investigated; their attitudes towards, knowledge of
and willingness to substitute generic medicines for inno-
vator drugs were investigated. Pharmacists’ perceptions of
the efficacy of generic medicines and how pharmacists feel
about the current national policy on generic substitution
was also analysed.
Ethical approval
The manuscript does not contain clinical studies or patient
data. The Ethics Committee of the Medical University of
Warsaw does not require consent (and does not issue
opinions) for this kind of research [19].
Method
Sampling and study representativeness
A description of the study including a detailed sampling
method to make the study as representative as possible as
well as observational error estimations are presented
below.
Sampling consisted of selecting individual units (phar-
macies) to make up the statistical sample, representative
for the general population. Stratified sampling was selected
to enable the best geographic representativeness of the
study. In stratified sampling, the general population is
broken down into strata and then independent samples are
randomly selected from each separate stratum. Stratifica-
tion was based on the location of pharmacies and the whole
of Poland was divided into 16 different regions. A list of
pharmacies in Poland, with a special focus on their location
(i.e. their province), was used as the sampling frame.
The size of individual strata was determined from the
actual numerical distribution of pharmacies throughout
Poland. According to the Central Statistical Office, there
were 11,999 community pharmacies in Poland in 2012.
Table 1 presents data on the number of community phar-
macies in each region. The number of interviews to be
conducted with pharmacists in individual regions was
calculated from a sample size of 802 units, whose structure
was identical to that of the general population. Moreover,
the study was performed according to pre-defined sampling
assumptions to make it representative in all regions.
Observational error
The acceptable observational error in a representative study
was determined according to relevant statistical rules and
relates to population size, study sample size, and the
acceptable confidence level. The study covered all com-
munity pharmacies operating in Poland. Given the subject
matter of the study—generic substitution—respondents
were pharmacists who held an MSc in pharmacy and
worked at one of the selected pharmacies.
The acceptable observational error for the sample size
used in this study was calculated using the following
formula:
n ¼ P 1  Pð Þ
e2
Z2
þ P 1Pð Þ
N
where: P—estimated proportion in the general popula-
tion—a standard value of 50 %; e—maximum accept-
able observational error (calculated); n—study size (802);
N—population size (11,999); Z—Z value was calculated
from the confidence level (1.96 at 95 % confidence level).
The study was conducted for 95 % confidence level and
50 % fraction per population value. Maximum observa-
tional error was estimated at 3.34 %. Observational error is
the maximum acceptable difference between the estimated
value of a parameter determined from a sample and the true
value in the population concerned. Therefore, actual values
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may differ from the study results by up to 3.34 percentage
points.
Interviews
The survey was conducted in October 2013 by telephone
interviews with 802 holders of MSc degrees in pharmacy
working at community pharmacies. These were structured
(standardized) interviews, i.e. the interviewer asked a pre-
defined list of questions.
The questionnaire used during the interviews was tested
for face and content validity by two public opinion research
experts, and adjusted after pilot tests with 50 pharmacists.
The final questionnaire included demographic questions as
well as specific questions concerning the experience and
opinions of pharmacists in the area of generic substitution.
The attitudes of pharmacists to various aspects of generic
substitution were analysed on a five-point Likert scale.
Respondents remained anonymous.
Statistical methods
Statistical analysis was performed using SPSS Statistics
v.21 (IBM). Because the Kołmogorow–Smirnow test
demonstrated statistically significant deviations from the
normal distribution of quantitative variables, nonparamet-
ric equivalents were used. Correlations between variables
were measured in the Spearman’s rho rank correlation
analysis, and the differences between mean values were
calculated with the Mann–Whitney U test. Nominal vari-
ables were measured using the Chi square test.
Results
The Mann–Whitney U test (Table 2) demonstrated a sig-
nificant difference between less experienced pharmacists
(practising for 1–5 years) compared to more experienced
pharmacists (11–15 years) (U = 9628.5, p = 0.013); less
experienced pharmacists were less likely to inform con-
sumers about the availability of cheaper generic substitutes.
A significant difference was also confirmed for pharmacists
with 1–5 versus 16–20 years of practice (U = 8610.5,
p = 0.001) and those with 1–5 versus C21 years of prac-
tice (U = 9925.5, p = 0.001).
Other factors—including sex, age, pharmacy status
(chain vs. independent pharmacy), and pharmacy loca-
tion—did not differentiate the respondents to a statistically
significant extent in terms of how frequently they informed
customers about their generic option (p[ 0.05).
Sixty-seven percent of respondents believed the efficacy
of cheaper generics was no worse than that of innovator
medicines, and around 3 % of respondents believed it may be
superior. Nearly 30 % of pharmacists claimed generics were
Table 1 Sampling
Sampling strata—regions General population Study sample
Number of community
pharmacies
Structure in % Number of community
pharmacies
Structure in %
Lodzkie province 864 7.20 58 7.23
Masovia province 1585 13.21 107 13.34
Lesser Poland province 1112 9.27 75 9.35
Silesia province 1395 11.63 93 11.60
Lublin province 805 6.71 54 6.73
Subcarpathia province 600 5.00 40 4.99
Podlaskie province 352 2.93 23 2.87
Holy Cross province 417 3.48 28 3.49
Lubusz province 304 2.53 20 2.49
Greater Poland province 1137 9.48 76 9.48
West Pomerania province 502 4.18 33 4.11
Lower Silesia province 970 8.08 65 8.10
Opole province 303 2.53 20 2.49
Kuyavia-Pomerania province 583 4.86 39 4.86
Pomerania province 682 5.68 45 5.61
Warmia-Masuria province 388 3.23 26 3.24
Poland 11,999 100 802 100
Source: based on the data from Local Data Bank of the Central Statistical Office in Poland (www.stat.gov.pl) and on the study results
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sometimes less effective; only 1 % claimed that generics
were typically less effective (Table 3, Q2).
If they were to buy a medicine for themselves, 25 % of
respondents stated that they would choose a cheaper gen-
eric drug, whereas 9 % expressed a preference for inno-
vator products. The majority of pharmacists (66 %) had no
a priori preferences and would decide on a case by case
basis (Table 3, Q3).
A significant correlation between the perception of
pharmacists for the therapeutic efficacy of generic versus
innovator medicines (Q2) and their positive attitude to
generic substitution (Q4) was demonstrated in the Spear-
man’s rho rank correlation analysis (Rho = 0.21,
p\ 0.001). The correlation was positive, i.e. pharmacists
who believed in the efficacy of generics were more likely
to be in favour of generic substitution, whenever the code
‘NZ’ (indicating ‘do not substitute’) is absent from a
prescription.
Two-thirds of pharmacists were in favour of generic
substitution unless contraindications existed (i.e. a ‘‘do not
substitute’’ note on the prescription). 32 % of respondents
were in favour and 32 % opposed imposing a legal obli-
gation on pharmacists to inform consumers about the
availability of generics (Table 4).
Table 2 Frequency of sharing information on generic substitution among the study population (n = 802)
Sociodemographic characteristics Total (n) Q1: How often do you inform consumers that they can buy a cheaper generic
instead of the prescribed innovator product (assuming that both products are
available for sale at the pharmacy)? n (%)
Never Rare Sometimes Often Always
Gender
Female 700 (100 %) 0 (0 %) 24 (3.4 %) 66 (9.4 %) 326 (46.6 %) 284 (40.6 %)
Male 102 (100 %) 0 (0 %) 6 (5.9 %) 13 (12.7 %) 41 (40.2 %) 42 (41.2 %)
Age
25–34 y 245 (100 %) 0 (0 %) 7 (2.9 %) 35 (14.3 %) 113 (46.1 %) 90 (36.7 %)
35–44 y 312 (100 %) 0 (0 %) 11 (3.5 %) 21 (6.7 %) 150 (48.1 %) 130 (41.7 %)
45–54 y 182 (100 %) 0 (0 %) 9 (4.9 %) 14 (7.7 %) 81 (44.5 %) 78 (42.9 %)
55–64 y 51 (100 %) 0 (0 %) 1 (2 %) 8 (15.7 %) 20 (39.2 %) 22 (43.1 %)
65 y and over 12 (100 %) 0 (0 %) 2 (16.7 %) 1 (8.3 %) 3 (25 %) 6 (50 %)
Pharmacy status
Chain pharmacy 262 (100 %) 0 (0 %) 11 (4.2 %) 32 (12.2 %) 108 (41.2 %) 111 (42.4 %)
Independent pharmacy 540 (100 %) 0 (0 %) 19 (3.5 %) 47 (8.7 %) 259 (48 %) 215 (39.8 %)
Years of practice as a pharmacist
1–5 184 (100 %) 0 (0 %) 12 (6.1 %) 33 (18 %) 78 (42.6 %) 61 (33.3 %)
6–10 235 (100 %) 0 (0 %) 12 (5.1 %) 18 (7.7 %) 117 (49.8 %) 88 (37.4 %)
11–15 129 (100 %) 0 (0 %) 3 (2.3 %) 12 (9.3 %) 54 (41.9 %) 60 (46.5 %)
16–20 118 (100 %) 0 (0 %) 1 (0.8 %) 5 (4.2 %) 61 (51.7 %) 51 (43.2 %)
20 and more 136 (100 %) 0 (0 %) 3 (2.2 %) 11 (8.1 %) 57 (41.9 %) 65 (47.8 %)
Pharmacy location
Urban area of over 500,000 inhabitants 138 (100 %) 0 (0 %) 6 (4.3 %) 17 (12.3 %) 64 (46.4 %) 51 (37 %)
Urban area of 100,000–500,000 inhabitants 184 (100 %) 0 (0 %) 4 (2.2 %) 16 (8.7 %) 97 (52.7 %) 67 (36.4 %)
Urban area of up to 100,000 inhabitants 387 (100 %) 0 (0 %) 14 (3.6 %) 38 (9.8 %) 162 (41.9 %) 173 (44.7 %)
Rural area 93 (100 %) 0 (0 %) 6 (6.5 %) 8 (8.6 %) 44 (47.3 %) 35 (37.6 %)
Total 802 (100 %) 0 (0 %) 30 (3.7 %) 79 (9.9 %) 367 (45.8 %) 326 (40.6 %)
Table 3 Attitude of pharmacists towards generics (n = 802)
Survey question/answers n %
Q2: Do you think generics are:
Typically less effective than innovator medicines 6 0.9
Sometimes less effective than innovator medicines 233 29
Equally effective as innovator medicines 538 67
Sometimes more effective than innovator medicines 22 2.7
Typically more effective than innovator medicines 3 0.4
Q3: When buying drugs yourself, you typically choose:
Generics 201 25
Either a generic or a innovator medicine 530 66
Innovator medicines 71 9
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A closer look was taken at those respondents who were
against imposing a legal obligation on pharmacists to
inform consumers of their generic option. These pharma-
cists were shown to be more sceptical with regard to the
therapeutic efficacy of generics compared to innovator
drugs (Q2 vs. Q5, U = 24,669, p\ 0.001).
Likewise, those against generic substitution considered
generics to be less effective than innovator products com-
pared to those in favour of generic substitution unless
contraindications existed (Q2 vs. Q4, U = 10,976,
p\ 0.001).
Out of 802 respondents, 507 had a full understanding of
the European Medicines Agency (EMA) definition of
generics, i.e. they marked all five statements correctly that
define a generic product in Question 6 [20, 21]. Almost all
respondents agreed that the active substance(s) and thera-
peutic indications of a generic and the originator brand must
be identical (99 and 97 % respectively). The vast majority of
pharmacists knew that the pharmaceutical form and route of
administration for generics and the originator brands had to
be the same (91 %). However, 31 % of respondents were not
aware that the dosage of generics and originator brands must
also be the same (Fig. 1).
During the next stage of analysis, respondents were
divided into two groups: the first group demonstrated only
a partial knowledge of the proper definition of generic
medicines and included those pharmacists who selected
1–4 out of the 5 statements defining a generic in Question
6. The second group included those respondents who cor-
rectly recognised all 5 criteria of a generic medicine
(Table 5).
A significant association was found to exist between
respondents being able to fully define a generic medicine
and their years of practice as a pharmacist (v2(4) = 30.28,
p\ 0.001). Respondents with 1–5 years of practice were
more familiar with all definition criteria. The longer
respondents were in practice, the less likely they were to be
familiar with all criteria defining a generic. Respondents
with only partial knowledge of the definition of generics
had typically been practicing for 6–20 years (Table 5).
Knowledge of all five criteria defining a generic medi-
cine (Q6, full vs. partial knowledge) did not differentiate
the respondents to a statistically significant extent in terms
of how frequently pharmacists informed consumers about
the availability of generic medicines (Q1, p[ 0.05) or in
terms of being for or against generic substitution (Q4,
p[ 0.05).
Discussion
This study shows that the majority of pharmacists in
Poland always (40 %) or often (46 %) inform consumers
about a generic option. Pharmacists with more professional
experience are more likely to inform customers, this was
also confirmed in another recent Polish study carried out in
Lodzkie province [22]. Factors such as: sex, age, pharmacy
status (chain pharmacy vs. independent pharmacy), and
pharmacy location did not differentiate the respondents to a
statistically significant level in terms of frequency with
which they made consumers aware that they could opt for
generic substitution (p[ 0.05). Chong et al. [23] arrived at
similar conclusions after testing 500 randomly selected
Australian pharmacies from across the country. He repor-
ted no significant differences in the frequency of recom-
mending generic substitution between urban and rural
areas, or between pharmacists who worked at different
types of pharmacies (e.g. independently owned, banner
group). In this study, pharmacists stated that, when possi-
ble, they offered generic substitutes for almost all (96.4 %)
innovator products prescribed [23].
In 2012, generics accounted for a 70 % market share in
Germany and around 60–68 % in Poland, the United
Kingdom, the Netherlands and Denmark (other European
countries had a lower generic market share) [24]. Poland is
a country with a mature generic medicine market, however,
the percentage share of pharmacists who always offered
generic substitution was higher in some other countries [25,
26]. This could be explained by the poor enforcement of
the statutory obligation to inform patients about generic
substitution. Additionally, this study has revealed that
pharmacists in Poland have different opinions on whether
they should be legally bound to inform patients that a
cheaper equivalent is available.
Table 4 Responses of pharmacists to questions exploring their perceptions of generic policy (n = 802)
Survey question/statement n (%)
Strongly
disagree
Disagree Neutral Agree Strongly
agree
Q4: I am in favour of generic substitution (whenever the code
‘NZ’ is absent from the prescription)
13 (1.6 %) 45 (5.6 %) 206 (25.7 %) 396 (49.4 %) 142 (17.7 %)
Q5: I believe pharmacists should be legally bound to inform
consumers about the generic substitute of the prescribed
innovator medicine
93 (11.6 %) 160 (20.0 %) 293 (36.5 %) 173 (21.6 %) 83 (10.3 %)
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Nearly one-third of all respondents were against
imposing a legal obligation on pharmacists to inform
consumers about generics, which may explain why some
pharmacists have been reluctant to adhere to these laws.
Pharmacists who were against this legal obligation were
shown to have a more negative attitude to the therapeutic
efficacy of generic versus brand name drugs. Therefore,
negative attitudes (and the resulting potential non-compli-
ance) to the legal obligation to inform consumers of gen-
eric availability may be attributed, at least to some extent,
to the poor perception of generic efficacy. The uptake of
generics could be greater if these pharmacists had more
positive attitudes to the therapeutic efficacy of generic
drugs.
In Chong et al.’s 2010 study in Australia [26], 93.7 % of
respondents declared they were ready to offer generic sub-
stitutes unless it was explicitly forbidden. In Poland, this
figure was less than 70 %. Australia has implemented sev-
eral education campaigns among pharmacists, which may
have contributed to the high percentage of pharmacists in
favour of generic substitution. One example being the
National Prescribing Service, the Pharmaceutical Society of
Australia, and the Pharmacy Guild of Australia work
together and now supply information and guidelines on
generic medicines to community pharmacists [27]. These
education initiatives are aimed to consolidate knowledge
and confidence among pharmacists to teach consumers
about how to safely and appropriately use generics. For
instance, a ‘‘Generic medicines are an equal choice’’ cam-
paign was launched in 2008, where a generics tool kit was
sent to each community pharmacist [28]. The tool kit con-
tained practical guides on brand substitution and ancillary
labels with which pharmacists found it easier to inform
consumers about the active ingredients of dispensed
medicines [29]. Due to the positive effects of these actions,
similar measures could be contemplated in Poland or else-
where. Moreover, since August 2008, pharmacists in Aus-
tralia are encouraged to dispense cheaper brands by being
paid a financial incentive whenever they offer a substi-
tutable, premium-free PBS medicine (the incentive is AUD
1.50 as of August 2010) [30].
Around 63 % of pharmacists in Poland had full
knowledge of the definition of generics. Analysis revealed
something particularly noteworthy—pharmacists in prac-
tice for longer were less able to fully define generic med-
icine. The same result was found in a 2012 study, on a
Fig. 1 Percentage of
pharmacists who agreed on the
following statements based on
the EMA definition of a generic
medicine (Q6, all statements
were correct) (n = 802)
Table 5 Time of practice vs. knowledge of the definition of generics (Q6, n = 802)
Years of practice intervals Total
1–5 years 6–10 years 11–15 years 16–20 years 21 years and more
Partial knowledge 43 (14.6 %) 90 (30.5 %) 51 (17.3) 64 (21.7 %) 47 (15.9 %) 295 (100 %)
Full knowledge 141 (27.8 %) 145 (28.6 %) 78 (15.4 %) 54 (10.7 %) 89 (17.5 %) 507 (100 %)
Total 184 (22.9 %) 235 (29.3 %) 129 (16.1 %) 118 (14.7 %) 136 (17.0 %) 802 (100 %)
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group of 625 pharmacists from New Zealand, by Babar
et al. [31]. However, both in Babar et al., and in this study,
better knowledge does not necessarily prompt pharmacists
to support generic substitution, and may not alter actual
dispensing habits.
In this study, the majority of respondents (67 %)
reported no difference in efficacy between generics and the
originator brands, whereas 31 % claimed that original
brands could be more effective than generics. Similarly
high percentages of pharmacists who believe in the higher
efficacy of innovator medicines can be observed in other
countries. In Babar et al.’s study, around 50 % of respon-
dents believed originator brands were more effective, and
around 70 % of respondents recognised generics as bioe-
quivalent to reference innovator medicines. In another
study, by Chong et al. [13], among Malaysian community
pharmacists, 21 % of all respondents supported the state-
ment that generic medicines were of inferior quality and
only around half of them believed that generics are thera-
peutically equivalent to the innovator drug. The results of
the study by Babar et al. [31] and Chong et al. [13], suggest
that the negative opinion of at least part of the respondents
concerning the quality and efficacy of generics may per-
haps be attributed to the fact that a large percentage of
those pharmacists were in both cases unaware (or ques-
tioned the fact) that any product approved as a generic
equivalent had to be bioequivalent to the originator drug by
definition. In this study, almost one-third of respondents
believed in the occasional superiority of innovator medi-
cines. Future research should investigate the factors
underlying the negative perceptions of some Polish phar-
macists towards generics to discover whether this is due to
personal prejudices or negative patient feedback.
Conclusion
This study delivers baseline data to support improvements
to the generic substitution policy in Poland, however,
conclusions could also be relevant to decision-makers from
other EU countries.
In order to be clinically based, the decision whether to
substitute should be grounded in appropriate medical evi-
dence. Therefore, clear-cut guidelines and recommenda-
tions for safe generic substitution, which prescribing
physicians or pharmacists could rely upon, are essential.
Specifically, a guide for health professionals describing
therapeutically equivalent and non-equivalent medicinal
products, such as the Orange Book in the US, in order to
contain the risk of errors and irregularities around generic
substitution should be created. Guidelines of this kind
should be developed at a national level, based on the rel-
evant domestic legislation [32].
The main focus should be on the education of health
professionals. It is their awareness and sensitivity to
warning symptoms that is decisive for the effectiveness of
Adverse Drug Reaction (ADR) reporting. Comprehensive
awareness-raising campaigns should therefore be consid-
ered. If the impact of such education initiatives is evalu-
ated, it will also be easier to investigate the causes of
negative perceptions of generic efficacy, such as personal
prejudice or negative patient feedback.
Finally, pharmacotherapy monitoring systems in a
framework of pharmaceutical care should be considered to
ensure that any safety or quality concerns could be easily
identified. In the future, pharmacists may find it easier to
monitor the safety of pharmacotherapy by relying on an
integrated IT system, which provides access to patient’s
medical history and treatment, used by outpatient clinics,
hospitals, and pharmacies. This will help identify possible
therapy-related risks.
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